{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:23:19Z","timestamp":1787026999837,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:00:00Z","timestamp":1726444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have become a prevalent tool in anti-tumor therapy in recent years. They may cause immune-related adverse events (irAEs) including potentially life-threatening cardiovascular toxicities such as myocarditis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>In this report, we describe a 69-year-old man with recurrent esophageal cancer who developed myocarditis after receiving three cycles of sintilimab combined with nab-paclitaxel. Despite a rising cardiac troponin I (cTnI), he initially reported no discomfort. He was later suspected of having with sintilimab-induced myocarditis. Although treatment with methylprednisolone reduced his cTnI levels, he still experienced significant discomfort. Moreover, he developed pneumonia and septic shock.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In our literature search to identify all reported cases of sintilimab-associated adverse events involving myocarditis, we found 14 patients, including those with esophageal cancer, thymoma, lung cancer, gastric cancer, hepatobiliary carcinoma, and chordoma. The primary treatment for ICI-induced cardiotoxicity is methylprednisolone. However, the long-term or high-dose use of steroids can also induce side effects, which have not been the focus of these case reports. This is the first reported case of asymptomatic immune-mediated myocarditis occurring during the treatment of esophageal cancer with sintilimab. It is also the first to address the side effects of methylprednisolone used in the treatment of sintilimab-related myocarditis. To facilitate an early diagnosis, regular monitoring is required during sintilimab treatment. We should also focus on the prevention and management of adverse effects related to steroid use.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2024.1465395","type":"journal-article","created":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:10:15Z","timestamp":1726445415000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Sintilimab-induced myocarditis suspected in a patient with esophageal cancer and followed septic shock: case report and literature review"],"prefix":"10.3389","volume":"14","author":[{"given":"Qihao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiquan","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoqing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyuan","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qunjiang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiahong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,9,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac456","article-title":"Cardiovascular complications of immune checkpoint inhibitors for cancer","volume":"43","author":"Thuny","year":"2022","journal-title":"Eur Heart J"},{"key":"B2","doi-asserted-by":"publisher","first-page":"10948","DOI":"10.3390\/ijms231810948","article-title":"Cardiac toxicity associated with immune checkpoint inhibitors: A systematic review","volume":"23","author":"Cozma","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B3","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1097\/crd.0000000000000217","article-title":"Cardiac immune-related adverse events in immune checkpoint inhibition therapy","volume":"27","author":"Brumbaugh","year":"2019","journal-title":"Cardiol Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1016\/s0140-6736(18)30533-6","article-title":"Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis","volume":"391","author":"Moslehi","year":"2018","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.heliyon.2023.e16874","article-title":"A case of acute myocarditis induced by pd-1 inhibitor (Sintilimab) in the treatment of large cell neuroendocrine carcinoma","volume":"9","author":"Zheng","year":"2023","journal-title":"Heliyon"},{"key":"B6","doi-asserted-by":"publisher","first-page":"e33550","DOI":"10.1097\/md.0000000000033550","article-title":"Immune checkpoint inhibitor sintilimab-induced lethal myocarditis overlapping with myasthenia gravis in thymoma patient: A case report","volume":"102","author":"Wang","year":"2023","journal-title":"Medicine"},{"key":"B7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.3390\/jcdd10100422","article-title":"Sintilimab-induced myocarditis in a patient with gastric cancer: A case report and literature review","volume":"10","author":"Liu","year":"2023","journal-title":"J Cardiovasc Dev Dis"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1080\/08923973.2023.2228480","article-title":"A case report and literature review on respiratory failure with immune checkpoint inhibitors: A life-threatening adverse event","volume":"45","author":"Lin","year":"2023","journal-title":"Immunopharmacol immunotoxicology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s12890-023-02417-4","article-title":"A case of subclinical immune checkpoint inhibitor-associated myocarditis in non-small cell lung cancer","volume":"23","author":"Hu","year":"2023","journal-title":"BMC pulmonary Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.950801","article-title":"Myocarditis and myositis\/myasthenia gravis overlap syndrome induced by immune checkpoint inhibitor followed by esophageal hiatal hernia: A case report and review of the literature","volume":"9","author":"Yin","year":"2022","journal-title":"Front Med"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e31873","DOI":"10.1097\/md.0000000000031873","article-title":"Severe cardiotoxicity in 2 patients with thymoma receiving immune checkpoint inhibitor therapy: A case report","volume":"101","author":"Liu","year":"2022","journal-title":"Medicine"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2022.955527","article-title":"Immune myocarditis related to sintilimab treatment in a patient with advanced lung adenocarcinoma: A case report","volume":"9","author":"Lin","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.995121","article-title":"Sintilimab induced iciam in the treatment of advanced hcc: A case report and analysis of research progress","volume":"13","author":"Ji","year":"2022","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.797009","article-title":"Sintilimab-induced myocarditis overlapping myositis in a patient with metastatic thymoma: A case report","volume":"8","author":"Yang","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.682262","article-title":"Immune myocarditis overlapping with myasthenia gravis due to anti-pd-1 treatment for a chordoma patient: A case report and literature review","volume":"12","author":"Liang","year":"2021","journal-title":"Front Immunol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"793","DOI":"10.21037\/apm-20-2449","article-title":"Immune checkpoint inhibitor-induced myocarditis in lung cancer patients: A case report of sintilimab-induced myocarditis and a review of the literature","volume":"10","author":"Bi","year":"2021","journal-title":"Ann palliative Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.21037\/atm.2020.01.79","article-title":"Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (Sintilimab) therapy for lung adenocarcinoma","volume":"8","author":"Xing","year":"2020","journal-title":"Ann Transl Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1253463","article-title":"Sintilimab-induced inflammatory myopathy in a patient with esophageal cancer: A case report","volume":"14","author":"Hong","year":"2023","journal-title":"Front Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e068714","DOI":"10.1136\/bmj-2021-068714","article-title":"Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (Orient-15): multicentre, randomised, double blind, phase 3 trial","volume":"377","author":"Lu","year":"2022","journal-title":"Bmj"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.111611","article-title":"Cardiac myosin-specific autoimmune T cells contribute to immune-checkpoint-inhibitor-associated myocarditis","volume":"41","author":"Won","year":"2022","journal-title":"Cell Rep"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2023.2219895","article-title":"Myocarditis and autoimmunity","volume":"21","author":"Matsumori","year":"2023","journal-title":"Expert Rev Cardiovasc Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1175809","article-title":"Immune-related adverse events associated with nab-paclitaxel\/paclitaxel combined with immune checkpoint inhibitors: A systematic review and network meta-analysis","volume":"14","author":"Hao","year":"2023","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-7568(21)00255-5","article-title":"Efficacy and safety of carboplatin with nab-paclitaxel versus docetaxel in older patients with squamous non-small-cell lung cancer (Capital): A randomised, multicentre, open-label, phase 3 trial","volume":"2","author":"Kogure","year":"2021","journal-title":"Lancet Healthy Longev"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-020-05710-8","article-title":"Multinational association of supportive care in cancer (Mascc) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors","volume":"28","author":"Suarez-Almazor","year":"2020","journal-title":"Support Care Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-023-01320-5","article-title":"Cardiovascular toxicity of immune checkpoint inhibitors: A guide for clinicians","volume":"46","author":"Raschi","year":"2023","journal-title":"Drug Saf"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: asco guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208623","article-title":"Severe sepsis and septic shock","volume":"369","author":"Angus","year":"2013","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1465395\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,16]],"date-time":"2024-09-16T00:10:18Z","timestamp":1726445418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2024.1465395\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,16]]},"references-count":27,"alternative-id":["10.3389\/fonc.2024.1465395"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2024.1465395","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,16]]},"article-number":"1465395"}}